New technology introduced to speed up discovery of new therapies

A new throughput biochemical assay platform has been developed to speed up the discovery of new therapies.

Cambio's Transcreener HTS assays and iuvo Microconduit array technology has been developed by BellBrook Labs, which use no radioactive compounds. There are several applications available to researchers, including cell viability, cell motility and cell differentiation assays using immunocytostaining and live cell assay staining techniques.

This offers an extensive and validated method of screening drug targets such as protein kinases, as well as other nucleotide-dependent enzymes targeted for therapeutic intervention. The technology is based on single-step, homogenous fluorescence assays providing sensitive detection, which offers verified results.

There is also BellBrook's iuvo Microconduit Arrays available to scientists, which takes a completely different approach by enabling the use of highly miniaturised, advanced cell models and functional assays which more accurately replicate in vivo processes.

The benefit of this technology is that it combines microfluidics with the advantages of normal pipetting techniques, simplifying work with primary cells, 3D matrices and co-culture, as well as reducing dilution of secreted signalling molecules.

Posted by Ben Evans